NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

TSX · Drug Manufacturers - Specialty & Generic · CAD

Curaleaf Holdings, Inc. (CURA.TO) Stock Analysis

Curaleaf Holdings, Inc. (CURA.TO) is a Drug Manufacturers - Specialty & Generic stock listed on TSX and quoted in Canadian Dollar.

CURA.TO

CA$13.72

+CA$0.54 (+4.10%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CURA.TO with… →

CURA.TO Key Statistics

As of Sep 4, 2026
Trading
Open
CA$13.18
Previous Close
CA$13.18
Day's Range
13.15–13.72
52-Week Range
7.77–20.93
Volume
139.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.64
Valuation
Market Cap
CA$3.63B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.76
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.22
Financials (FY)
Revenue (FY)
CA$1.27B−4.96%
Net Income (FY)
−CA$273.36M
Profit marginThe share of revenue left as profit after all costs and taxes.
−2.63%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
233.54M
1-Year Return
+18.17%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
173.45K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CURA.TO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+34.12%
2025+52.23%
2024−59.35%
2023−5.49%
2022−48.41%
2021 (partial year)−39.31%

As of September 4, 2026.

CURA.TO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025CA$1.27B−CA$273.36M−21.6%
2024CA$1.33B−CA$238.17M−17.8%
2023CA$1.35B−CA$281.20M−20.9%
2022CA$1.28B−CA$370.10M−29.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$1.27BCA$631.02MCA$25.45M−CA$273.36M−21.6%
2024CA$1.33BCA$640.78MCA$24.74M−CA$238.17M−17.8%
2023CA$1.35BCA$614.45MCA$42.88M−CA$281.20M−20.9%
2022CA$1.28BCA$626.42MCA$64.99M−CA$370.10M−29.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CURA.TO Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricCURA.TODrug Manufacturers - Specialty & Generic medianvs median
P/S ratio2.762.3020% above
Profit margin−2.63%−3.14%0.5 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Curaleaf Holdings, Inc. (CURA.TO) carries a market capitalisation of CA$3.63B. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 5,554.

Over the past 52 weeks the price has ranged from CA$7.77 to CA$20.93. CURA.TO last closed at CA$13.72 on September 4, 2026. That is +CA$0.54 (+4.10%) against the previous close. The latest close sits 76.58% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to CA$1.27B. That is −4.96% against the prior fiscal year, when revenue was CA$1.33B. The same year closed with a net loss of CA$273.36M. The reported profit margin is −2.63%. That is 0.5 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −0.22.

Across the 4 fiscal years on file, revenue moves from CA$1.28B in 2022 to CA$1.27B in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 2.76 times revenue. On price-to-sales that is 20.32% above the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.64. Annualized volatility over the trailing 5 years is 88.41%. Over the trailing twelve months the price has returned +18.17%. Measured over 5 years, that is −21.25% a year compounded.

Growth & Income

The record shows no dividend for CURA.TO.

2026 is still running; the price is +34.12% year to date. Across the complete calendar years on file, 2025 returned +52.23% and 2024 returned −59.35%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Curaleaf Holdings, Inc. (CURA.TO) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Curaleaf Holdings, Inc. CURA.TO CA$3.63B —
Takeda Pharmaceutical Company Limited TAK CA$58.92B —
Teva Pharmaceutical Industries Limited TEVA CA$42.37B 60.6
Haleon plc HLN CA$42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Curaleaf Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Curaleaf Holdings, Inc.

Curaleaf Holdings, Inc. engages in the retail and wholesale of cannabis products in the United States and internationally. The company operates licensed cultivation; and pharma-grade cannabis processing and manufacturing facilities. It also supplies cannabis on a wholesale basis to Australia, New Zealand, the United Kingdom and various European countries, including Germany, Italy, Poland, the Czech Republic, Switzerland, Sweden and Norway. In addition, the company operates a medical cannabis clinic and holds a pharmacy license. It serves the medical and adult-use cannabis markets through retail and wholesale channels. The company is based in Stamford, Connecticut.

Visit website →